Nanfang-Chunfu Children's Institute of Hematology & Oncology

CancerFax acts as your single Mandarin-speaking coordinator for the entire Nanfang-Chunfu Children's Institute journey. You begin by sharing your child's complete haematology records through our secure intake — for thalassemia patients this includes hemoglobin electrophoresis, thalassemia genotyping, complete transfusion history, iron studies, current iron chelation therapy and cardiac and liver iron assessment; for acute leukaemia patients this includes bone marrow biopsy findings, flow cytometry, cytogenetics, molecular profiling and prior treatment history. Our clinical team reviews the case and confirms whether the institute's pediatric HSCT pathway is genuinely the right clinical fit, with particular attention to donor availability — for the haploidentical HSCT pathway that accounts for nearly 70 per cent of the institute's transplants, a parent typically serves as donor and must also undergo evaluation.

Once your consultation is confirmed, CancerFax prepares your full pre-travel pack: the institute's official cost estimate translated into English (shared with you without any CancerFax mark-up), Chinese visa documentation for the patient, accompanying parents and donor, accredited translation of your home-country reports, accommodation guidance in Dongguan for the typical 3 to 6 month HSCT stay, and travel logistics via Hong Kong, Guangzhou, Shenzhen or Macau airports. We remain your single point of contact through admission, pre-transplant conditioning, HSCT, engraftment, discharge and long-term post-transplant follow-up. Where useful, we will openly compare Nanfang-Chunfu alongside parallel pediatric HSCT pathways at Lu Daopei Hospital, Beijing GoBroad Boren Hospital and Shenzhen Children's Hospital, and discuss emerging gene therapy options for thalassemia and sickle cell disease where these may eventually become available. There is no fee to the family for any of this coordination.

Nanfang-Chunfu Children's Institute has published a 97.6 per cent overall survival rate for its innovative Complementary Transplantation Protocol for thalassemia — described by the institute as the world's best result for thalassemia transplantation. For context, international thalassemia HSCT outcomes from leading centres typically range from approximately 80 to 95 per cent overall survival depending on patient risk factors (age, prior iron overload, donor type, conditioning protocol). The institute's published outcome of 97.6 per cent overall survival places it at or above the highest end of internationally reported pediatric thalassemia HSCT outcomes. The key clinical factor driving these outcomes is the institute's deep expertise in haploidentical HSCT — meaning that families without a fully matched sibling donor (which is the situation for most international thalassemia patients) can still access transplantation using a parent as donor. CancerFax can help your family compare these outcomes alongside other internationally recognised thalassemia transplant centres, and where gene therapy for transfusion-dependent thalassemia is a clinically appropriate alternative consideration, we will discuss those options too.

Haploidentical hematopoietic stem cell transplantation (also called haplo-HSCT) is a transplant where the donor is a half-matched family member — typically a parent, but sometimes a half-matched sibling. The 'half-match' refers to the HLA (human leukocyte antigen) compatibility, with haploidentical donors matching on 5 of 10 key HLA antigens compared with 10 of 10 for a fully matched donor. Haploidentical HSCT is particularly important for international pediatric patients because: (i) most children do not have a fully matched sibling donor available; (ii) finding a matched unrelated donor through international donor registries can take months and is often unsuccessful for patients of South Asian, Middle Eastern, African or mixed ancestry where donor registry representation is limited; and (iii) haploidentical transplantation can typically be planned within weeks using a parent as donor. At Nanfang-Chunfu Children's Institute, haploidentical HSCT accounts for 69.89 per cent of all transplants, using the Tαβ+ Cell-Depleted HSCT (TDH) protocol that removes specific T-cell subsets from the donor graft to reduce graft-versus-host disease risk while preserving the anti-leukaemia immune effect. This deep expertise is one of the institute's most clinically meaningful differentiators.

Yes. Nanfang-Chunfu Children's Institute accepts foreign-language pediatric haematology records and provides written opinions before any travel commitment. The process involves submitting your child's records through the international service channel ([email protected]), which CancerFax facilitates on your behalf with accredited translation into Chinese. The institute's clinical team led by Professor Chunfu Li reviews the case and provides a written opinion covering HSCT eligibility, the proposed transplant protocol (Complementary Transplantation Protocol for thalassemia, Tαβ+ Cell-Depleted HSCT for haploidentical pathway, or alternative protocol), donor matching considerations, conditioning regimen, and estimated cost and timeline. CancerFax can also arrange parallel remote second opinions from Lu Daopei Hospital, Beijing GoBroad Boren Hospital and other internationally recognised pediatric HSCT centres so the family can make a well-informed decision before committing to international travel.

As a Chinese pediatric hematology specialty institute, Nanfang-Chunfu Children's Institute offers HSCT at substantially lower cost than equivalent pediatric HSCT in the United States, United Kingdom, Western Europe or the Gulf. Chinese pediatric HSCT at high-volume specialty centres typically ranges in total cost (inclusive of pre-transplant evaluation, donor evaluation, conditioning chemotherapy, transplant, engraftment hospitalisation, post-transplant supportive care and the first phase of follow-up) at a fraction of equivalent care in high-cost healthcare markets. Costs are broadly comparable with Lu Daopei Hospital and Beijing GoBroad Boren Hospital, though specific pricing depends on the transplant protocol chosen, donor type (haploidentical typically less expensive than matched unrelated donor), complication contingency and total length of stay. CancerFax shares the institute's official cost estimates with you at no extra charge and without any CancerFax mark-up, and we are happy to compare them openly with other Chinese pediatric HSCT centres and emerging gene therapy options for transfusion-dependent thalassemia and sickle cell disease before any decision is made. For families considering thalassemia HSCT specifically, we always recommend asking for a 'complication contingency' estimate alongside the base HSCT cost, because pre-transplant iron overload management and post-transplant infection management can add meaningfully to total cost.